Choice of Posterpresentations with Pegaspargase

1608 Premedication Prior to Peg-Asparaginase Is Cost-Effective for Pediatric Leukemia Patients

Meghan McCormick, Jillian Lapinski, Erika Friehling, and Ken Smith WEBCAST (ASH-registration required)

1885 Antimetabolic Cooperativity with l-Asparaginase and Tyrosine Kinase Inhibitor Quizartinib to Eradicate Persistant FLT3-ITD Leukemic Cells

Quentin Fovez, Raeeka Khamari, Anne Trinh,et al. WEBCAST (ASH-registration required)

1900 Premedication and Longer Infusion Time Do Not Reduce the Incidence of Hypersensitivity Reactions to Pegaspargase

Catherine Hughes, Valeria Bernardo, Susanne Youssef, et al. WEBCAST (ASH-registration required)

2074 Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Qingqing Cai, Huiqiang Huang,  Panpan Liu, et al. WEBCAST (ASH-registration required)

2833 Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, Elias Jabbour, Nitin Jai, et al. WEBCAST (ASH-registration required)